Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Researchers Find Risk Markers for… >
Researchers Find Risk Markers for Erectile Dysfunction Following Radiation in Prostate Cancer

Published: September 27, 2012.
By The Mount Sinai Hospital / Mount Sinai School of Medicine
http://www.mountsinai.org

In the first study of its kind, a research team led by Mount Sinai School of Medicine and Albert Einstein College of Medicine of Yeshiva University discovered 12 genetic markers associated with the development of erectile dysfunction (ED) in prostate cancer patients who were treated with radiation. The findings, to be published online September 27, 2012, in advance of the October 1, 2012 print issue in the International Journal of Radiation Oncology• Biology• Physics, the official scientific journal of the American Society for Radiation Oncology, are an important step towards helping clinicians determine the best course of treatment for prostate cancer patients and may lead to the development of therapies that alleviate side effects.

The main treatments for prostate cancer – surgery, brachytherapy (seed implants) and external beam radiation therapy – are all very effective at curing prostate cancer. Unfortunately, each treatment places patients at risk for ED. According to the National Cancer Institute, the prevalence of erectile dysfunction following external beam radiation for prostate cancer ranges from 65 percent to 85 percent. The Prostate Cancer Foundation estimates prevalence of ED following seed therapy at 25 to 50 percent. Many men will be able to regain their potency with time and treatments, but doctors would like to identify which men may be more likely to develop this side effect.

In the first large scale Genome-Wide Association Study to identify single nucleotide polymorphisms (SNPs) associated with susceptibility for the development of erectile dysfunction following radiotherapy for prostate cancer, researchers conducted a two-part study, first, to discover the candidate genetic markers of side effect risk, and second, to confirm which of those markers are replicated in a second group of patients. In the first group of prostate cancer patients, which included 132 men who developed erectile dysfunction after radiotherapy and 103 men similarly treated who did not develop erectile dysfunction, they found a set of genetic markers associated with erectile dysfunction. In the second part of the study, which examined 128 patients who developed erectile dysfunction after radiotherapy and 102 who did not, researchers confirmed that 12 SNPs were associated with erectile dysfunction.

"Thankfully, current treatments for prostate cancer offer excellent rates of long-term survival, so patients and their physicians have a choice about which treatment path to take," said Barry Rosenstein, PhD, Professor of Radiation Oncology, Mount Sinai School of Medicine. "However, the risk of developing erectile dysfunction after radiation treatment is highly variable, suggesting there may be a genetic component to determining that risk. Our study confirms that specific markers make certain patients more susceptible to this side effect."

Patients in the study cohort were given one of three treatments: internal radiotherapy, known as brachytherapy; brachytherapy plus external beam radiation; or external beam radiation alone. They were followed for an average length of nearly four years to determine level of sexual function after treatment.

Interestingly, the 12 SNPs identified in this study were located near genes that seem to be related to erectile function rather than related to radiation response. The researchers conclude that these SNPs may affect genes that sensitize a patient to developing erectile dysfunction when exposed to radiation during therapy.

"Prostate cancer screening and treatment are undergoing major shifts," said Harry Ostrer, MD, Professor of Pathology and Genetics at Albert Einstein College of Medicine and Director of Genetic and Genomic Testing at Montefiore Medical Center and co-principal investigator of the study. "This is part of our ongoing effort to identify men at highest risk for disease, identify the aggressive tumors that would be responsive to therapy, and to improve quality of life for men with indolent prostate cancers who might benefit from active surveillance, rather than therapy."

The authors indicate that examination of a large, independent cohort of similarly treated patients will be necessary to definitively determine which SNPs to include as part of a clinically useful predictive test to identify which men are at greatest risk for developing erectile dysfunction following prostate cancer radiotherapy. The researchers are also evaluating the impact of radiation treatment on urinary complications and proctitis, the inflammation of the rectum.


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Cancer 
9/27/12 
Predicting Erectile Dysfunction from Prostate Cancer Treatment
By American Society for Radiation Oncology
Researchers have identified 12 DNA sequences that may help doctors determine which men will suffer from erectile dysfunction (ED) following radiation therapy for prostate cancer. Identifying these patients in …
Therapy 
4/1/14 
Medication Does Not Help Prevent ED Following Radiation Therapy for Prostate Cancer
By The JAMA Network Journals
Among men undergoing radiation therapy for prostate cancer, daily use of the erectile dysfunction drug tadalafil, compared with placebo, did not prevent loss of erectile function, according to a …
Patients 
4/4/14 
Brachytherapy Helps Maintain Erectile Function in Prostate Cancer Patients Without Compromising Treatment Outcomes
By European Society for Radiotherapy and Oncology (ESTRO)
Vienna, Austria: The use of permanent brachytherapy, a procedure where radioactive sources are placed inside the prostate, into or near to the tumour, preserves erectile function in approximately 50% …
Radiation 
1/6/12 
Proton Therapy Effective Prostate Cancer Treatment
By American Society for Radiation Oncology
Proton therapy, a type of external beam radiation therapy, is a safe and effective treatment for prostate cancer, according to two new studies published in the January issue of …
Radiation 
12/18/13 
Computer-controlled Table Could Direct Radiotherapy to Tumours While Sparing Vital Organs
By Institute of Cancer Research
Swivelling patients around on a computer-controlled, rotating table could deliver high doses of radiotherapy to tumours more quickly than current methods, while sparing vulnerable organs such as the heart, …
Treatment 
7/8/14 
Variations in Key Gene Predict Cancer Patients' Risk for Radiation-induced Toxicity
By The Mount Sinai Hospital / Mount Sinai School of Medicine
(NEW YORK – July 8, 2014) Key genetic variants may affect how cancer patients respond to radiation treatments, according to a study published this week in Nature Genetics. The …
Prostate 
9/16/14 
Prostate Cancer Patients Surveyed 5 Years After Vessel-sparing RT Report Preserved Sexual Function
By American Society for Radiation Oncology
San Francisco, September 15, 2014—A comparison of five-year sexual function outcomes, as reported by patients treated with external beam radiotherapy (EBRT) versus combination EBRT plus brachytherapy, indicates that the …
Radiotherapy 
11/15/13 
Italian Study Examines Clinical Predictors of Acute Urinary Symptoms After Radiotherapy for Prostate
By European Association of Urology
Arnhem, The Netherlands - An interim study by Italian researchers showed that using a modelling programme together with IPSS and dosage measure can predict the severity of acute urinary …
Prostate 
1/26/12 
Brachytherapy Reduced Death Rates in High-risk Prostate Cancer Patients, Study Finds
By Thomas Jefferson University
Brachytherapy for high-risk prostate cancers patients has historically been considered a less effective modality, but a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests …
Treatment 
3/16/10 
Increased Radiation Dose Does Not Increase Long-term Side Effects for Prostate Cancer Patients
By Massachusetts General Hospital
Boosting the radiation dose given to prostate cancer patients to a level that cut tumor recurrence in half did not increase the severity of side effects reported by patients …
Satisfaction 
9/16/14 
Prostate Cancer Patients Who Receive Hypofractionated RT Report Consistent QoL
By American Society for Radiation Oncology
San Francisco, September 15, 2014—Prostate cancer patients who received hypofractionated (HPFX) radiation therapy (RT) reported that their quality of life, as well as bladder and bowel function were at …
Treatment 
10/8/13 
Recommended Treatment Regimen for Bone Metastases Not Widely Used
By The JAMA Network Journals
Justin E. Bekelman, M.D., of the University of Pennsylvania Perelman School of Medicine, Philadelphia, and colleagues conducted a study to examine whether single-fraction radiation treatment, shown to be as …
 
8/18/14 
Upgrading Electronic Monitoring, Downgrading Probation
By SAGE Publications
Under the Coalition Government which came to power in Britain in May 2010, major changes in the community supervision of offenders are underway in England and Wales. Under the …
 
7/22/14 
Communication Between Nostril/Skin Microbiome Bacteria Can Influence Pathogen Behavior
By Forsyth Institute
CAMBRIDGE, Mass., July 22, 2014--A team of scientists has made an important discovery about the molecular interactions that occur between generally benign species of Propionibacterium bacteria and the pathogenic …
 
7/17/14 
Acupuncture And Moxibustion Reduces Neuronal Edema in Alzheimer's Disease Rats
By Neural Regeneration Research
Aberrant Wnt signaling is possibly related to the pathological changes in Alzheimer's disease (AD). Axin and β-catenin protein is closely related to Wnt signaling. Zhou Hua and his team, …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition